Safety of Ombitasvir/Paritaprevir/Ritonavir+dasabuvir in Chronic Hepatitis C Patients With HCV Genotype 1 Infection

Acta Poloniae Pharmaceutica - Poland
doi 10.32383/appdr/105681
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Polish Pharmaceutical Society

Related search

Profile of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir in the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

A Real-Life Data on the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +Ribavirin in Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Serbia

Vojnosanitetski Pregled
MedicinePharmacology
2019English

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for Chronic HCV Infection in US Veterans With Psychiatric Disorders

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Real-World Experience With Ombitasvir/Paritaprevir Boosted With Ritonavir and Possibly Combined With Dasabuvir and Ribavirin in HCV Infection

Clinical and Experimental Hepatology
Hepatology
2016English

Drug-Drug Interactions Between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir With or Without Dasabuvir

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2015English

Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin in Treatment of Chronic Hepatitis C Patients With End Stage Renal Disease on Regular Hemodialysis

International Journal of Medical Arts
2020English

Time to Viral Suppression Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin

Journal of Viral Hepatitis
VirologyHepatologyInfectious Diseases
2016English

Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin for 24 Weeks in Patients With HCV GT4 and Compensated Cirrhosis (AGATE-I Part II)

Health Science Reports
2019English

Trend of Estimated Glomerular Filtration Rate During Ombistasvir/Paritaprevir/Ritonavir Plus Dasabuvir ± Ribavirin in HIV/HCV Co-Infected Patients

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy